BriaCell Therapeutics Statistics Share Statistics BriaCell Therapeutics has 1.76M
shares outstanding. The number of shares has increased by 229.33%
in one year.
Shares Outstanding 1.76M Shares Change (YoY) 229.33% Shares Change (QoQ) 82.67% Owned by Institutions (%) 0% Shares Floating 1.7M Failed to Deliver (FTD) Shares 25,938 FTD / Avg. Volume 20.06%
Short Selling Information The latest short interest is 351.05K, so 20% of the outstanding
shares have been sold short.
Short Interest 351.05K Short % of Shares Out 20% Short % of Float 20.16% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -18722.71 and the forward
PE ratio is -0.49.
BriaCell Therapeutics's PEG ratio is
238.89.
PE Ratio -18722.71 Forward PE -0.49 PS Ratio 0 Forward PS 4.8 PB Ratio -51.99 P/FCF Ratio -5.04 PEG Ratio 238.89
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for BriaCell Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.49,
with a Debt / Equity ratio of 0.
Current Ratio 0.49 Quick Ratio 0.49 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-413.44 Employee Count 16 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -92.81% in the
last 52 weeks. The beta is 1.47, so BriaCell Therapeutics's
price volatility has been higher than the market average.
Beta 1.47 52-Week Price Change -92.81% 50-Day Moving Average 12.13 200-Day Moving Average 45.76 Relative Strength Index (RSI) 42.06 Average Volume (20 Days) 129,315
Income Statement
Revenue n/a Gross Profit -114.04K Operating Income -46.02K Net Income -6.62K EBITDA -45.91K EBIT -46.02K Earnings Per Share (EPS) -4.28
Full Income Statement Balance Sheet The company has 862.09K in cash and 0 in
debt, giving a net cash position of 862.09K.
Cash & Cash Equivalents 862.09K Total Debt n/a Net Cash n/a Retained Earnings -85.44M Total Assets 17M Working Capital 10.45M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -24.13M
and capital expenditures -456.8K, giving a free cash flow of -24.58M.
Operating Cash Flow -24.13M Capital Expenditures -456.8K Free Cash Flow -24.58M FCF Per Share -22.41
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields BCTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for BCTX is $40,
which is 408.3% higher than the current price. The consensus rating is "Strong Buy".
Price Target $40 Price Target Difference 408.3% Analyst Consensus Strong Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 25, 2025. It was a
backward
split with a ratio of 1:10.
Last Split Date Aug 25, 2025 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -10.91 Piotroski F-Score 1
